Symposium: Vaccine Delivery and Immune Response

17 Sept 2024 | Vestar

HomeParticipantsMarketplaceAgenda

Lotte Coelmont

Research manager

KULeuven Rega Instituut

Leuven, Belgium

2 profile visits

My organisation

KU Leuven Rega Instituut

KU Leuven Rega Instituut

Academic institution

Leuven, Belgium

The MVVD (Molecular Vaccinology & Vaccine Discovery) team of Prof. Kai Dallmeier (at the Rega Institute, KU Leuven) focuses on the development of vaccines for neglected and emerging pathogens such as Zika virus (Kum et al. Nature PJ Vaccines 2018), Ebola (Lemmens et al., NPJ Vaccines, 2023) and SARS-CoV-2 (Sanchez-Felipe et al. Nature 2020; Sharma et al. Nature Comms. 2022), using the live-attenuated yellow fever YF17D vaccine as vector. Thermostable and easy to manufacture plasmid-launched versions thereof aim to tackle vaccine shortage and unmet public health needs faced by people living in LMIC.
Read more

About me

Lotte Coelmont, PhD, Research and Innovation Manager (IOF) at the KU Leuven, Rega Institute for Medical Research, Laboratory of Virology and Antiviral Chemotherapy.

The focus of this research lab is on the development of novel antiviral and vaccination strategies against multiple viruses. She is co-founder of AstriVax, a spin-off of the KU Leuven which further develops the PLLAV vaccine platform technology to clinical phase.

As IOF fellow, she supports the valorization activities of the research group, entailing a.o. scouting for funding opportunities (EU, NIH/NIAID, BMGF, CEPI, FWO), proposal writing and coordination, project management, increasing visibility of research, coordinating contract research.

My organisation

KULeuven Rega Instituut